Silyvit-E140 mg + 200 IU

Silyvit-E is a nutritional/dietary supplement combination marketed for the following uses:

• Supportive liver health (widely used, evidence-limited): Silyvit-E is traditionally used as an adjunct to support liver function in individuals with chronic liver conditions (e.g., alcoholic liver disease, non-alcoholic fatty liver disease, viral hepatitis) and to provide antioxidant protection to hepatocytes. Clinical trial evidence for silymarin's hepatoprotective benefit is mixed and not conclusive; it is not a substitute for evidence-based treatment of diagnosed liver disease.
• Antioxidant supplementation (established use of the vitamin E component): DL-alpha tocopherol supplies vitamin E, an established dietary antioxidant, and may be used to supplement dietary intake or address mild vitamin E insufficiency when directed by a physician.
• Adjunct/general wellness use: Often used alongside other measures (lifestyle modification, alcohol avoidance, treatment of the underlying liver condition) rather than as monotherapy for any diagnosed disease.

Silyvit-E is not FDA-approved as a prescription drug for the treatment of any specific liver disease; it is regulated and marketed as a dietary/nutritional supplement in most markets, including Bangladesh.

Each unit of Silymarin and DL-Alpha Tocopherol typically contains:

• Silymarin (standardized milk thistle, Silybum marianum, seed extract) - a complex of flavonolignans including silybin, silydianin, and silychristin.
• DL-alpha tocopherol - a synthetic form of vitamin E.

Exact strengths vary by manufacturer and product; refer to the specific product label for the precise amount of silymarin (mg) and vitamin E (mg or IU) contained.

Silyvit-E is a combination oral nutritional supplement containing silymarin, a standardized flavonolignan extract derived from milk thistle (Silybum marianum) seeds, and DL-alpha tocopherol, a synthetic form of vitamin E. It is formulated as a hepatoprotective and antioxidant supplement, most commonly taken as capsules or tablets.

Silymarin has long been used in traditional medicine for liver-related complaints, and modern research has explored its antioxidant, membrane-stabilizing, and anti-inflammatory properties. Vitamin E is a well-established fat-soluble antioxidant vitamin that protects cell membranes from oxidative damage. The combination is intended to provide complementary antioxidant support, particularly for individuals with liver conditions or increased oxidative stress, though it should not replace prescribed medical treatment.

Silyvit-E belongs to the therapeutic class of hepatoprotective and antioxidant nutritional supplements (herbal extract combined with a vitamin E antioxidant).

Silymarin and DL-Alpha Tocopherol combines two agents with complementary antioxidant activity:

• Silymarin: Proposed mechanisms include scavenging of free radicals, inhibition of lipid peroxidation in hepatocyte cell membranes, stabilization of the hepatocyte membrane against toxin entry, stimulation of hepatocyte protein synthesis (supporting regeneration), and modulation of inflammatory pathways within the liver. Silymarin is poorly absorbed orally (bioavailability is low), undergoes enterohepatic recirculation, and is largely excreted in bile/feces with minor renal elimination.
• DL-alpha tocopherol (vitamin E): Acts as a lipid-soluble chain-breaking antioxidant, protecting polyunsaturated fatty acids within cell membranes from oxidative free-radical damage. It is absorbed with dietary fat via the intestinal lymphatic system, transported bound to lipoproteins, stored in adipose tissue and liver, and metabolized hepatically with excretion mainly in bile.

Together, these components are proposed to reduce oxidative stress on hepatocytes, though robust clinical evidence of meaningful disease-modifying benefit remains limited.

Silyvit-E should be taken orally, swallowed whole with a glass of water, preferably with or after food to aid absorption of the vitamin E component and reduce the chance of stomach upset. Do not crush or chew unless the product is specifically designed to be chewed.

Silyvit-E has the following well-documented or clinically notable interaction considerations:

• Anticoagulants/antiplatelet agents (e.g., warfarin, aspirin, clopidogrel): Silymarin has a theoretical mild effect on platelet function, and high-dose vitamin E may modestly increase bleeding tendency; concurrent use should be discussed with the prescriber, and monitoring for bleeding or INR changes is advisable where relevant.
• Drugs metabolized via CYP3A4/CYP2C9 pathways (e.g., certain statins): Silymarin may have a weak inhibitory effect on these hepatic enzymes; clinical significance is generally considered low at typical supplement doses but caution is advised with narrow-therapeutic-index drugs.
• Antidiabetic medications: Silymarin has been reported to have a mild blood-glucose-lowering effect in some studies; monitor blood glucose if used concurrently with antidiabetic therapy.
• Other vitamin E-containing products/multivitamins: Concurrent use may lead to cumulative vitamin E intake exceeding recommended limits; avoid duplicating vitamin E supplementation.

Silyvit-E is generally well tolerated. Reported side effects include:

• Common: Mild gastrointestinal upset (nausea, bloating, diarrhea, abdominal discomfort), headache.
• Less common: Allergic skin reactions (itching, rash, urticaria), particularly in individuals sensitive to the Asteraceae/Compositae plant family.
• Rare (mainly associated with high-dose or prolonged vitamin E intake): Increased bleeding tendency, fatigue, blurred vision.

Discontinue use and seek medical advice if signs of an allergic reaction (rash, swelling, difficulty breathing) occur.

Data on the use of Silyvit-E during pregnancy and breastfeeding are limited. As a precaution, Silyvit-E should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use. Similarly, use during breastfeeding should only occur after consulting a physician, weighing benefits against potential unknown risks to the nursing infant. Vitamin E at recommended dietary levels is generally considered safe in pregnancy and lactation, but supplemental high-dose intake should be avoided unless advised by a physician.

The following precautions apply to the use of Silyvit-E:

• Limited evidence of benefit: Evidence supporting silymarin's clinical hepatoprotective effect in diagnosed liver disease is mixed and evidence-limited despite widespread traditional use; Silyvit-E should not be used as a substitute for physician-directed, evidence-based treatment of significant hepatic conditions - seek proper medical evaluation for liver disease.
• Bleeding risk: Use with caution in patients on anticoagulant/antiplatelet therapy (see Interactions) due to a theoretical mild effect on clotting/platelet function.
• Hormone-sensitive conditions: Silymarin has shown mild estrogenic activity in limited in-vitro/preclinical data; use with caution and discuss with a physician in patients with a history of hormone-sensitive conditions (e.g., breast, uterine, or ovarian cancer, endometriosis).
• Vitamin E intake limits: Avoid exceeding the recommended total daily vitamin E intake from combined dietary and supplement sources, as high-dose vitamin E has been associated with increased bleeding risk and other adverse effects in some studies.
• Allergy history: Use caution in individuals with known allergy to plants of the Asteraceae/Compositae family (see Contraindications).

Overdose of Silyvit-E is uncommon but may occur with excessive or prolonged intake, particularly of the vitamin E component. Possible features include gastrointestinal upset, fatigue, headache, blurred vision, and an increased tendency to bleed or bruise. There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic based on clinical presentation.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: Safety and efficacy of Silyvit-E in children have not been well established; use is not generally recommended unless specifically directed by a pediatrician.

Elderly: No specific dose adjustment is established for elderly patients; use with routine caution given the higher likelihood of concurrent medications (see Interactions).

Hepatic impairment: Silyvit-E is often used in patients with liver disease for its proposed hepatoprotective properties, but it does not replace evidence-based treatment of the underlying condition; use under medical supervision.

Renal impairment: No well-established dose adjustment; use with routine caution.

The duration of Silyvit-E use depends on the reason for use and individual response, and should be guided by a physician. It is often used for several weeks to a few months as an adjunct supplement, with periodic reassessment of ongoing need and effect, particularly when used to support liver health.

Hepatoprotective herbal extract (silymarin) combined with an antioxidant vitamin (vitamin E, DL-alpha tocopherol) - nutritional/dietary supplement class.

Silymarin and DL-Alpha Tocopherol works through two complementary antioxidant mechanisms: silymarin scavenges reactive oxygen species, inhibits lipid peroxidation of hepatocyte cell membranes, stabilizes the cell membrane against entry of hepatotoxins, and may stimulate hepatocyte protein synthesis to support liver cell regeneration. DL-alpha tocopherol (vitamin E) acts as a lipid-soluble, chain-breaking antioxidant that protects polyunsaturated fatty acids in cell membranes throughout the body from oxidative damage, complementing silymarin's hepatocyte-focused antioxidant action.

Silyvit-E is not routinely recommended for use in children, as its safety and efficacy in the pediatric population have not been well established through controlled studies. If considered necessary, use should occur only under the direction and supervision of a pediatrician, who will weigh potential benefits against the limited safety data available in children.